Identification of small-molecule inhibitors of the SARS-CoV-2 RBD–ACE2 interaction by structure- and affinity-based screening
Bioscience Reports · 05.11.2026
DOI: 10.1042/bsr20260478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioscience Reports, online erschienen am 05.11.2026. Verfasst von Hisashi Murakami und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shizuoka Kenritsu Daigaku Yakugakubu Yakugaku Kenkyuin, Shizuoka, Japan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein mediates viral entry through its interaction with angiotensin-converting enzyme 2 (ACE2), making it an attractive target for antiviral intervention. However, the broad and relatively shallow ACE2-binding interface presents a challenge for small-molecule inhibitor discovery. In this study, we explored conserved regions outside the ACE2-binding interface as potential druggable sites for small-molecule inhibitors targeting the SARS-CoV-2 RBD. Structure-based virtual screening was performed using the structure of the SARS-CoV-1 RBD as a structural surrogate, and selected compounds were evaluated using a newly established affinity-based assay on diazirine-modified amorphous carbon plates. Evaluation of 175 virtual hits identified eight RBD-binding compounds. Among them, only RABI-1 inhibited RBD–ACE2 interaction in a Calu-3 cell-based binding assay without affecting ACE2 expression or cell viability. Evaluation of structural analogs of RABI-1 led to the identification of RABI-3, which showed stronger inhibitory activity compared with RABI-1. In addition, RABI-3 inhibited the interaction between ACE2 and RBDs derived from multiple SARS-CoV-2 variants in an AlphaLISA immunoassay and suppressed pseudovirus infection in Calu-3 cells. These findings support the feasibility of targeting regions of the RBD outside the ACE2-binding interface as a strategy for identifying small-molecule inhibitors of SARS-CoV-2 entry.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shizuoka Kenritsu Daigaku Yakugakubu Yakugaku Kenkyuin, Shizuoka, Japan.
Förderung
- MEXT | Japan Society for the Promotion of Science
Zitieren
APA
Murakami, H., Makita, S., Fukai, R., Ichida, T., Koyama, K., Ohta, K., Takebayashi, Y., Yoshimori, A., Ogo, N., & Asai, A. (2026). Identification of small-molecule inhibitors of the SARS-CoV-2 RBD–ACE2 interaction by structure- and affinity-based screening. Bioscience Reports. https://doi.org/10.1042/bsr20260478
Vancouver
Murakami H, Makita S, Fukai R, Ichida T, Koyama K, Ohta K, et al. Identification of small-molecule inhibitors of the SARS-CoV-2 RBD–ACE2 interaction by structure- and affinity-based screening. Bioscience Reports. 2026. doi:10.1042/bsr20260478
BibTeX
@article{Murakami2026,
author = {Murakami, Hisashi and Makita, Suzuka and Fukai, Ryota and Ichida, Taiki and Koyama, Kaito and Ohta, Katsumi and Takebayashi, Yasushi and Yoshimori, Atsushi and Ogo, Naohisa and Asai, Akira},
title = {Identification of small-molecule inhibitors of the SARS-CoV-2 RBD–ACE2 interaction by structure- and affinity-based screening},
journal = {Bioscience Reports},
year = {2026},
doi = {10.1042/bsr20260478}
}
EUVIMED